💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…
Profile for Neurocrine Biosciences, Inc. (NBIX)
« Back to company indexNBIX Chatter Timeline
Stock Ticker for NBIX
Most Active Tweeters for NBIX
| User | Tweets |
|---|---|
| @mediasentiment | 11 |
| @MarcJacksonLA | 6 |
| @Estimize | 4 |
| @Allstocknews | 4 |
| @newsfilterio | 4 |
Recent Tweets for NBIX
 |
@mediasentiment $NBIX new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 204 May 8th 2021, 1:05pm |
 |
@ResearchPool $NBIX #Neurocrine Biosciences Inc. Continued Ingrezza Weakness, But Think It Can Turn A Corner: [...]… https://t.co/tOwPnI4s83 May 8th 2021, 1:05pm |
|
@mediasentiment $NBIX new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 37 May 8th 2021, 8:05am |
|
@mediasentiment $NBIX new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 972 May 7th 2021, 9:05pm |
 |
@Jarvis_Alerts $NBIX [Neurocrine Biosciences]: SVB Leerink Maintains Market Perform Lowers Price Target $110 --> 100 https://t.co/g0Ybj2if7z May 7th 2021, 12:05pm |
|
@Jarvis_Alerts $NBIX [Neurocrine Biosciences]: Morgan Stanley Maintains Overweight Lowers Price Target $125 --> 116 https://t.co/lK9goG1mt2 May 7th 2021, 12:05pm |
 |
@WallstWhispers We understand Barclays analyst Carter Gould upgraded Neurocrine Biosciences $NBIX to Overweight from Equal Weight w… https://t.co/8TJycRQ7jP May 6th 2021, 9:05pm |
 |
@BioMedReports Barclays analyst Carter Gould upgraded Neurocrine Biosciences $NBIX to Overweight from Equal Weight with an unchang… https://t.co/67BPZ3iHOz May 6th 2021, 9:05pm |
|
@mediasentiment $NBIX new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 722 May 6th 2021, 7:05pm |
 |
@newsfilterio Neurocrine upgraded at Barclays despite Q1 earnings miss $NBIX https://t.co/bM5Rfr6K2j May 6th 2021, 3:05pm |
 |
@MarketCurrents $NBIX - Neurocrine upgraded at Barclays despite Q1 earnings miss https://t.co/Z26alvBAQi May 6th 2021, 3:05pm |
|
@mediasentiment $NBIX new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 479 May 6th 2021, 2:05pm |
 |
@MarcJacksonLA $NBIX HC Wainwright Maintains Buy Rating On Neurocrine Biosciences, $140 PT https://t.co/IOOgwHmXmW May 6th 2021, 2:05pm |
|
@MarcJacksonLA $NBIX Oppenheimer Assigns a Buy Rating On Neurocrine Biosciences, $140 PT https://t.co/5ooyGyaYv5 May 6th 2021, 2:05pm |
|
@MarcJacksonLA $NBIX Barclays Upgrades Neurocrine Biosciences To Overweight From Equal Weight, $110 PT https://t.co/5knw0DdPkl May 6th 2021, 1:05pm |
 |
@HoganMullally RT @encodelp: $NBIX remains on track to initiate two studies with NBI-921352, Nav1.6 antagonist licensed from $XENE, this year https://t.co… May 6th 2021, 12:05pm |
|
@Jarvis_Alerts $NBIX [Neurocrine Biosciences]: Barclays Upgrades Equal-Weight --> Overweight Announces Price Target $110 https://t.co/K4CCv1ZW7W May 6th 2021, 12:05pm |
 |
@QuantData Barclays Upgrades Neurocrine Biosciences to Overweight, Announces $110 Price Target Related Tickers: $NBIX Read mo… https://t.co/9sXDIil57h May 6th 2021, 11:05am |
|
@newsfilterio $NBIX Barclays analyst Carter Gould upgrades Neurocrine Biosciences from Equal-Weight to Overweight and announces $110 price target. May 6th 2021, 11:05am |
 |
@Briefingcom $NBIX: Barclays ups to Overweight May 6th 2021, 10:05am |
 |
@BioWino RT @sbwcws: Neurocrine upgraded to Overweight from Equal Weight at Barclays $NBIX May 6th 2021, 10:05am |
 |
@sbwcws Neurocrine upgraded to Overweight from Equal Weight at Barclays $NBIX May 6th 2021, 10:05am |
 |
@SiteFocusHQ $NBIX Earnings Intelligence Analysis of recent earnings identified Neurocrine Biosciences, Inc (NASDAQ: NBIX ) busi… https://t.co/sG5TTW2TIu May 6th 2021, 4:05am |
 |
@EarningsAlley Neurocrine Biosciences, Inc. $NBIX held an earnings call on 5/5/2021. Here are the highlights: May 6th 2021, 4:05am |
 |
@SeekingAlpha $NBIX - Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q1 2021 Results - Earnings Call Transcript.… https://t.co/FtaatQQC2i May 6th 2021, 1:05am |
|
@SeekingAlpha $NBIX - Neurocrine Biosciences, Inc. 2021 Q1 - Results - Earnings Call Presentation. https://t.co/YBCAI4xWQl #trading #stockmarket #economy May 6th 2021, 1:05am |
 |
@EdgarInsider Alert [Press/News Current Report] / Form 8-K filed with the SEC $NBIX NEUROCRINE BIOSCIENCES INC https://t.co/DfCck87Miv May 5th 2021, 10:05pm |
|
@EdgarInsider Filing for 10-Q [Quarterly Report] has been made with the SEC: $NBIX NEUROCRINE BIOSCIENCES INC https://t.co/gMQ5yDRbJQ May 5th 2021, 10:05pm |
|
@Briefingcom $NBIX: Neurocrine Biosci misses by $0.29, misses on revs https://t.co/uBC0BAvCdn May 5th 2021, 10:05pm |
|
@mediasentiment $NBIX new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 1048 May 5th 2021, 8:05pm |
 |
@Estimize The most accurate $NBIX estimate is from Canaccord_163, beating 10 other analysts and the Wall Street Consensus - https://t.co/Eb9ymd3H90 May 5th 2021, 8:05pm |
|
@Estimize $NBIX misses the Estimize EPS Consensus by 42c and the Estimize Revenue Consensus by $14.69M. Reports FQ1 earnings… https://t.co/LG29e8Xuy9 May 5th 2021, 8:05pm |
|
@Estimize $NBIX reports FQ1 earnings of 33c EPS and $236.60M Revs - https://t.co/GbaaAakJx1 May 5th 2021, 8:05pm |
 |
@Allstocknews $NBIX New Form 10-Q for Neurocrine Biosciences, Inc. From our Stock News Alerts App May 5th 2021, 8:05pm |
 |
@encodelp $NBIX remains on track to initiate two studies with NBI-921352, Nav1.6 antagonist licensed from $XENE, this year https://t.co/OyZ29SsOWo May 5th 2021, 8:05pm |
 |
@otcdynamics $NBIX Neurocrine Biosciences Reports First Quarter 2021 Financial Results https://t.co/pmmdVAoeDC May 5th 2021, 8:05pm |
|
@mediasentiment $NBIX new alert at https://t.co/A7qrDarJHY #stocks #daytrading #NYSE #NASDAQ #market 868 May 5th 2021, 8:05pm |
 |
@Sanctuary_Bio $NBIX Ingrezza sales down for a 3rd quarter in a role, Ongentys flat sequentially (~$1M), increases opex guidance f… https://t.co/YPqcgQJAou May 5th 2021, 8:05pm |
 |
@fintel_io $NBIX / Neurocrine Biosciences files form 10-Q https://t.co/zFgofVxyvg May 5th 2021, 8:05pm |
|
@Allstocknews $NBIX Neurocrine Biosciences Reports First Quarter 2021 Financial Results From our Stock News Alerts App May 5th 2021, 8:05pm |
|
@MarcJacksonLA $NBIX Neurocrine Biosciences Reports 1Q 2021 Results https://t.co/yZh4S6pLfI May 5th 2021, 8:05pm |
|
@fintel_io $NBIX / Neurocrine Biosciences files form 8-K - Financial Statements and Exhibits, Results of Operations and Financ… https://t.co/kuL4wYgUnH May 5th 2021, 8:05pm |
 |
@FlashAlert_me $NBIX [15s. delayed] filed form 8-K on May 05, 16:05:00: Item2.02: Results of Operations & Financial Condition https://t.co/Oy14AL4wWj May 5th 2021, 8:05pm |
 |
@glitchbotio RT @MarketCurrents: $NBIX - Neurocrine Biosciences EPS misses by $0.24, misses on revenue https://t.co/R0BhGKkCVz May 5th 2021, 8:05pm |
 |
@MSollender $NBIX Neurocrine Biosciences Reports First Quarter 2021 Financial Results INGREZZA® (valbenazine) First Quarter 20… https://t.co/aE0jGbgfUz May 5th 2021, 8:05pm |
|
@MarketCurrents $NBIX - Neurocrine Biosciences EPS misses by $0.24, misses on revenue https://t.co/R0BhGKkCVz May 5th 2021, 8:05pm |
 |
@stock_titan $NBIX Neurocrine Biosciences Reports First Quarter 2021 Financial Results https://t.co/jKkNiQLN0R May 5th 2021, 8:05pm |
 |
@tinkStrategy RT @Sanctuary_Bio: should be a fun AH $NBIX - stabilization in Ingrezza sales (2 quarters in decline)? Traction on Ongentys? $OCUL - Dexte… May 5th 2021, 7:05pm |
 |
@earningsinfo $NBIX Neurocrine Biosciences Inc Q1 2021 Earnings Call https://t.co/cpGhfMwUmG May 5th 2021, 7:05pm |
 |
@AccesswireNews $NBIX Neurocrine Biosciences, Inc. to Host Earnings Call https://t.co/5OF61jAeum May 5th 2021, 6:05pm |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2021. All rights reserved.
Get the DrugPatentWatch Daily Briefing
Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …
Want insights into the biggest revenue-changing events?
Billions of dollars in sales can evaporate overnight as drug patents expire and competitors enter the market.
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
➤ Free Trial
